Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Purpose
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (previously untreated). Rituximab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Zanubrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. When zanubrutinib is used in MCL, the current standard of care is to continue administering the drug indefinitely until disease progression. This continuous treatment comes with clinical as well as financial toxicity, which could be especially detrimental in older patients. For patients who achieve a CR after initial zanubrutinib plus rituximab therapy, it may be safe and equally effective to stop treatment and restart zanubrutinib upon disease progression rather than continuing indefinitely in previously untreated older adult patients with MCL.
Condition
- Mantle Cell Lymphoma
Eligibility
- Eligible Ages
- Over 60 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Criteria
Inclusion Criteria:
- • Histologically confirmed mantle cell lymphoma with cyclin D1 (BCL1) expression by
immunohistochemical stains and/or t(11;14) by cytogenetics or fluorescence in situ
hybridization (FISH) as confirmed by the enrolling center
- Any stage allowed (stage I-IV)
- Presence of measurable disease, defined as >= 1 nodal lesion that is > 1.5
cm in longest diameter or >= 1 extranodal lesion that is > 1 cm in longest
diameter
- Steroids for management of mantle cell lymphoma are allowed up to a dose
of prednisone 100mg/day (or equivalent) for up to 7 days
- No prior systemic treatment for mantle cell lymphoma
- No prior radiation treatment for stage I MCL
- No prior exposure to a BTK inhibitor or anti-CD20 monoclonal antibody
- No prior stem cell transplant
- Age >= 70 years OR age >= 60 to < 70 years with comorbidities precluding
autologous stem cell transplantation (autoSCT) including at least one of
the following: a) cardiac ejection fraction (EF) < 45%, b) diffusing
capacity for carbon monoxide < 60% predicted; c) creatinine clearance < 70
but > 30ml/minute (min); d) Eastern Cooperative Oncology Group (ECOG)
performance status of 2, which poses an unacceptable risk of toxicity for
high-dose therapy and stem cell transplantation; or e) Cumulative Illness
Rating Scales (CIRS) total score > 6
- ECOG Performance Status 0-2
- Absolute neutrophil count (ANC) >= 750/mm^3 (without growth factor support
within 7 days)
- Platelet count >= 75,000/mm^3 (or >= 50,000/mm^3 for patients with bone
marrow involvement of lymphoma) without growth factor support or
transfusion within 7 days
- Creatinine clearance >= 30 mL/ min determined by either: a) Estimation
using the Cockcroft-Gault equation or b) Measurement by nuclear medicine
scan or 24 hour urine collection
- Total bilirubin =< 1.5 x upper limit of normal (ULN) (unless documented
Gilbert's syndrome)
- Aspartate transferase (AST) / alanine transaminase (ALT) =< 3 x ULN
- Patients should not be considered candidates for stem cell transplant or
must have declined a stem cell transplant strategy
- No clinically significant cardiovascular disease including the following
- Unstable angina within 3 months before registration
- New York Heart Association class III or IV congestive heart failure
- History of clinically significant arrhythmias (eg, sustained ventricular
tachycardia, ventricular fibrillation, torsades de pointes)
- QT correction formula (QTcF) > 480 msecs based on Fredericia's formula
- History of Mobitz II second-degree or third-degree heart block without a
permanent pacemaker in place
- Human immunodeficiency virus (HIV)-infected patients on effective
anti-retroviral therapy with undetectable viral load within 6 months are
eligible for this trial
- No active Hepatitis B or Hepatitis C infection. Patients with prior
hepatitis B virus (HBV) exposure (positive HBV core antibody and/or
surface antigen) are eligible if they have no detectable viral load, and
are taking appropriate prophylactic antiviral therapy to prevent
reactivation. Patients with history of hepatitis C virus (HCV) are
eligible if they have an undetectable HCV viral load
- Patients with a prior or concurrent malignancy whose natural history or
treatment does not have the potential to interfere with the safety or
efficacy assessment of the investigational regimen are eligible for this
trial
- No history of severe bleeding disorder such as hemophilia A, hemophilia B,
von Willebrand disease, or history of spontaneous bleeding requiring blood
transfusion or other medical intervention
- No history of stroke or intracranial hemorrhage within 6 months prior to
registration
- No disease significantly affecting gastrointestinal function such as
malabsorption syndrome, resection of the stomach or small bowel, bariatric
surgery procedures, symptomatic inflammatory bowel disease, or partial or
complete bowel obstruction. Patient must be able to swallow pills
- Potential trial participants should have recovered from major surgery
- No vaccination with a live vaccine within 35 days prior to registration
- No hypersensitivity to zanubrutinib or rituximab or any of the other
ingredients of the study drugs
- Chronic concomitant treatment with strong inhibitors of CYP3A4 is not
allowed on this study. Patients on strong CYP3A4 inhibitors must
discontinue the drug for 14 days prior to registration on the study.
- Chronic concomitant treatment with strong CYP3A4 inducers is not allowed.
Patients must discontinue the drug 14 days prior to the start of study
treatment
- Avoid use of moderate CYP3A4 inhibitors, PGP inhibitors, and moderate
CYP3A4 inducers
- Archival tissue must be available for submission in all patients for
histopathology review, though participation in correlative substudies is
optional
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Induction therapy (Zanubrutinib, rituximab) |
Patients receive zanubrutinib PO and rituximab IV on study. Patients undergo bone marrow biopsy and FDG PET/CT or CT throughout the trial. Patients may also undergo EDG and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial. |
|
|
Experimental Arm A (Zanubrutinib) |
Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
|
|
Active Comparator ARM B (Observation) |
Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. |
|
Recruiting Locations
Little Rock 4119403, Arkansas 4099753 72205
Site Public Contact
501-686-8274
Beverly Hills 5328041, California 5332921 90211
Los Angeles 5368361, California 5332921 90048
Site Public Contact
310-423-8965
Derby 4832745, Connecticut 4831725 06418
Fairfield 4834157, Connecticut 4831725 06824
Glastonbury 4835003, Connecticut 4831725 06033
Greenwich 4835395, Connecticut 4831725 06830
Guilford 4835512, Connecticut 4831725 06437
Hartford 4835797, Connecticut 4831725 06105
New Haven 4839366, Connecticut 4831725 06520
North Haven 4839704, Connecticut 4831725 06473
Stamford 4843564, Connecticut 4831725 06902
Torrington 4844309, Connecticut 4831725 06790
Trumbull 4844459, Connecticut 4831725 06611
Waterbury 4845193, Connecticut 4831725 06708
Waterford 8480031, Connecticut 4831725 06385
Newark 4143861, Delaware 4142224 19713
Newark 4143861, Delaware 4142224 19713
Atlanta 4180439, Georgia 4197000 30303
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30308
Site Public Contact
888-946-7447
Atlanta 4180439, Georgia 4197000 30322
Site Public Contact
404-778-1868
Atlanta 4180439, Georgia 4197000 30342
Site Public Contact
404-851-7115
Augusta 4180531, Georgia 4197000 30912
Johns Creek 6331909, Georgia 4197000 30097
Boise 5586437, Idaho 5596512 83706
Boise 5586437, Idaho 5596512 83712
Caldwell 5587698, Idaho 5596512 83605
Coeur d'Alene 5589173, Idaho 5596512 83814
Fruitland 5593708, Idaho 5596512 83619
Meridian 5600685, Idaho 5596512 83642
Nampa 5601933, Idaho 5596512 83687
Nampa 5601933, Idaho 5596512 83687
Post Falls 5604353, Idaho 5596512 83854
Sandpoint 5606401, Idaho 5596512 83864
Bloomington 4885164, Illinois 4896861 61704
Canton 4831990, Illinois 4896861 61520
Carthage 4886716, Illinois 4896861 62321
Chicago 4887398, Illinois 4896861 60612
Site Public Contact
312-355-3046
Danville 4889426, Illinois 4896861 61832
Decatur 4236895, Illinois 4896861 62526
Decatur 4236895, Illinois 4896861 62526
Dixon 4889959, Illinois 4896861 61021
Site Public Contact
815-285-7800
Effingham 4237727, Illinois 4896861 62401
Effingham 4237727, Illinois 4896861 62401
Eureka 4891310, Illinois 4896861 61530
Galesburg 4893392, Illinois 4896861 61401
Kewanee 4898433, Illinois 4896861 61443
Macomb 4900817, Illinois 4896861 61455
Mattoon 4244099, Illinois 4896861 61938
O'Fallon 4245926, Illinois 4896861 62269
Ottawa 4905006, Illinois 4896861 61350
Pekin 4905599, Illinois 4896861 61554
Peoria 4905687, Illinois 4896861 61615
Peru 4905770, Illinois 4896861 61354
Princeton 4906818, Illinois 4896861 61356
Shiloh 4249910, Illinois 4896861 62269
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
217-545-7929
Springfield 4250542, Illinois 4896861 62702
Site Public Contact
800-444-7541
Springfield 4250542, Illinois 4896861 62781
Urbana 4914570, Illinois 4896861 61801
Washington 4915545, Illinois 4896861 61571
Crown Point 4919451, Indiana 4921868 46307
Site Public Contact
219-310-2550
Dyer 4919820, Indiana 4921868 46311
Site Public Contact
219-924-8178
Hobart 4921476, Indiana 4921868 46342
Site Public Contact
219-947-1795
Hobart 4921476, Indiana 4921868 46342
Indianapolis 4259418, Indiana 4921868 46312
Munster 4924014, Indiana 4921868 46321
Site Public Contact
219-836-3349
Munster 4924014, Indiana 4921868 46321
Valparaiso 4927537, Indiana 4921868 46383
Ames 4846834, Iowa 4862182 50010
Site Public Contact
515-956-4132
Ames 4846834, Iowa 4862182 50010
Ankeny 4846960, Iowa 4862182 50023
Site Public Contact
515-241-3305
Boone 4849051, Iowa 4862182 50036
Site Public Contact
515-956-4132
Carroll 4850478, Iowa 4862182 51401
Clive 4852065, Iowa 4862182 50325
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-6727
Des Moines 4853828, Iowa 4862182 50309
Site Public Contact
515-241-3305
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-282-2200
Des Moines 4853828, Iowa 4862182 50314
Des Moines 4853828, Iowa 4862182 50314
Site Public Contact
515-241-3305
Fort Dodge 4857486, Iowa 4862182 50501
Site Public Contact
515-956-4132
Fort Dodge 4857486, Iowa 4862182 50501
Iowa City 4862034, Iowa 4862182 52242
Site Public Contact
800-237-1225
Jefferson 4862482, Iowa 4862182 50129
Site Public Contact
515-956-4132
Marshalltown 4866371, Iowa 4862182 50158
Site Public Contact
515-956-4132
Waukee 4880981, Iowa 4862182 50263
Site Public Contact
515-241-3305
Hays 4272782, Kansas 4273857 67601
Site Public Contact
785-623-5774
Kansas City 4273837, Kansas 4273857 66160
Lawrence 4274277, Kansas 4273857 66044
Olathe 4276614, Kansas 4273857 66061
Overland Park 4276873, Kansas 4273857 66210
Pittsburg 4277241, Kansas 4273857 66762
Salina 4278890, Kansas 4273857 67401
Topeka 4280539, Kansas 4273857 66606
Site Public Contact
785-295-8000
Westwood 4281639, Kansas 4273857 66205
Boston 4930956, Massachusetts 6254926 02115
Ann Arbor 4984247, Michigan 5001836 48106
Bay City 4985180, Michigan 5001836 48706
Brighton 4986994, Michigan 5001836 48114
Brighton 4986994, Michigan 5001836 48114
Canton 4987990, Michigan 5001836 48188
Canton 4987990, Michigan 5001836 48188
Chelsea 4988628, Michigan 5001836 48118
Chelsea 4988628, Michigan 5001836 48118
Clarkston 4988997, Michigan 5001836 48346
Detroit 4990729, Michigan 5001836 48201
Farmington Hills 4992523, Michigan 5001836 48334
Farmington Hills 4992523, Michigan 5001836 48336
Site Public Contact
248-551-7695
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48503
Flint 4992982, Michigan 5001836 48532
Lapeer 4998842, Michigan 5001836 48446
Livonia 4999837, Michigan 5001836 48154
Macomb 5000473, Michigan 5001836 48044
Mount Pleasant 5002714, Michigan 5001836 48858
Petoskey 5005484, Michigan 5001836 49770
Pontiac 5006166, Michigan 5001836 48341
Royal Oak 5007804, Michigan 5001836 48073
Site Public Contact
248-551-7695
Saginaw 5007989, Michigan 5001836 48601
Tawas City 5011900, Michigan 5001836 48764
Troy 5012639, Michigan 5001836 48085
Site Public Contact
248-551-7695
Ypsilanti 5015688, Michigan 5001836 48106
Ypsilanti 5015688, Michigan 5001836 48197
Bemidji 5017822, Minnesota 5037779 56601
Brainerd 5019116, Minnesota 5037779 56401
Coon Rapids 5022025, Minnesota 5037779 55433
Deer River 5024099, Minnesota 5037779 56636
Duluth 5024719, Minnesota 5037779 55805
Hibbing 5030005, Minnesota 5037779 55746
Site Public Contact
218-786-3308
Maplewood 5036588, Minnesota 5037779 55109
Minneapolis 5037649, Minnesota 5037779 55407
Minneapolis 5037649, Minnesota 5037779 55415
Saint Cloud 5044407, Minnesota 5037779 56303
Saint Louis Park 5045021, Minnesota 5037779 55416
Saint Paul 5045360, Minnesota 5037779 55101
Saint Paul 5045360, Minnesota 5037779 55102
Sandstone 5045908, Minnesota 5037779 55072
Virginia 5051468, Minnesota 5037779 55792
Woodbury 5053358, Minnesota 5037779 55125
Cape Girardeau 4379966, Missouri 4398678 63703
Chesterfield 4381072, Missouri 4398678 63017
Site Public Contact
314-205-6936
City of Saint Peters 4407237, Missouri 4398678 63376
Creve Coeur 4382837, Missouri 4398678 63141
Kansas City 4393217, Missouri 4398678 64108
Site Public Contact
816-404-4375
Kansas City 4393217, Missouri 4398678 64116
Site Public Contact
913-588-3671
Kansas City 4393217, Missouri 4398678 64154
Lee's Summit 4394870, Missouri 4398678 64064
Springfield 4409896, Missouri 4398678 65804
Site Public Contact
417-269-4520
Springfield 4409896, Missouri 4398678 65807
Site Public Contact
417-269-4520
St Louis 4407066, Missouri 4398678 63110
St Louis 4407066, Missouri 4398678 63128
St Louis 4407066, Missouri 4398678 63129
St Louis 4407066, Missouri 4398678 63136
Anaconda 5637146, Montana 5667009 59711
Billings 5640350, Montana 5667009 59101
Bozeman 5641727, Montana 5667009 59715
Great Falls 5655240, Montana 5667009 59405
Kalispell 5660340, Montana 5667009 59901
Missoula 5666639, Montana 5667009 59804
Bellevue 5063805, Nebraska 5073708 68123
Omaha 5074472, Nebraska 5073708 68118
Site Public Contact
402-559-5600
Omaha 5074472, Nebraska 5073708 68198
Lebanon 5088597, New Hampshire 5090174 03756
Buffalo 5110629, New York 5128638 14263
Camillus 4833098, New York 5128638 13031
Site Public Contact
315-472-7504
East Syracuse 5116079, New York 5128638 13057
Site Public Contact
315-472-7504
Mineola 5127134, New York 5128638 11501
New York 5128581, New York 5128638 10016
New York 5128581, New York 5128638 10065
Site Public Contact
212-746-1848
Rochester 5134086, New York 5128638 14642
Site Public Contact
585-275-5830
Webster 5143495, New York 5128638 14580
Chapel Hill 4460162, North Carolina 4482348 27599
Durham 4464368, North Carolina 4482348 27710
Site Public Contact
888-275-3853
Bismarck 5688025, North Dakota 5690763 58501
Fargo 5059163, North Dakota 5690763 58103
Fargo 5059163, North Dakota 5690763 58122
Fargo 5059163, North Dakota 5690763 58122
Columbus 4509177, Ohio 5165418 43210
Lawton 4540737, Oklahoma 4544379 73505
Site Public Contact
877-231-4440
Tulsa 4553433, Oklahoma 4544379 74146
Site Public Contact
918-505-3200
Newberg 5742726, Oregon 5744337 97132
Ontario 5744166, Oregon 5744337 97914
Oregon City 5744253, Oregon 5744337 97045
Portland 5746545, Oregon 5744337 97213
Portland 5746545, Oregon 5744337 97225
Providence 5224151, Rhode Island 5224323 02903
Site Public Contact
401-444-1488
Westerly 5225631, Rhode Island 5224323 02891
Boiling Springs 4571805, South Carolina 4597040 29316
Charleston 4574324, South Carolina 4597040 29425
Easley 4577263, South Carolina 4597040 29640
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29605
Greenville 4580543, South Carolina 4597040 29615
Greer 4580599, South Carolina 4597040 29650
Seneca 4595346, South Carolina 4597040 29672
Sioux Falls 5231851, South Dakota 5769223 57104
Sioux Falls 5231851, South Dakota 5769223 57117-5134
Salt Lake City 5780993, Utah 5549030 84112
Saint Johnsbury 5240656, Vermont 5242283 05819
Richmond 4781708, Virginia 6254928 23235
Richmond 4781708, Virginia 6254928 23298
Edmonds 5793427, Washington 5815135 98026
Issaquah 5798487, Washington 5815135 98029
Seattle 5809844, Washington 5815135 98122
Ashland 5244247, Wisconsin 5279468 54806
Eau Claire 5251436, Wisconsin 5279468 54701
Johnson Creek 5257996, Wisconsin 5279468 53038
La Crosse 5258957, Wisconsin 5279468 54601
Madison 5261457, Wisconsin 5279468 53718
Madison 5261457, Wisconsin 5279468 53792
Marshfield 5261969, Wisconsin 5279468 54449
Milwaukee 5263045, Wisconsin 5279468 53226
Site Public Contact
414-805-3666
Minocqua 5263156, Wisconsin 5279468 54548
Mukwonago 5263965, Wisconsin 5279468 53149
New Berlin 5264381, Wisconsin 5279468 53151
Site Public Contact
414-805-0505
Oconomowoc 5265499, Wisconsin 5279468 53066
Site Public Contact
262-928-7878
Rice Lake 5268798, Wisconsin 5279468 54868
Stevens Point 5274644, Wisconsin 5279468 54482
Waukesha 5278052, Wisconsin 5279468 53188
Weston 5278693, Wisconsin 5279468 54476
More Details
- NCT ID
- NCT05976763
- Status
- Recruiting
- Sponsor
- Alliance for Clinical Trials in Oncology
Detailed Description
PRIMARY OBJECTIVE: I. To compare time to first progression or death (progression free survival [PFS]1) with continuous treatment (Arm A) and time to second progression or death (PFS2) with intermittent treatment that is restarted at first progression (Arm B). KEY SECONDARY OBJECTIVE: I. To compare overall survival between patients who achieve a complete remission (CR) with induction therapy subsequently treated with continuous treatment versus (vs.) intermittent treatment as part of maintenance therapy. SECONDARY OBJECTIVES: I. To determine overall response rate (ORR) and CR rate to induction therapy with zanubrutinib and rituximab in previously untreated MCL. II. To determine adverse events during induction and post-induction in each study arm (Arm A and B) by Common Terminology Criteria for Adverse Events (CTCAE) 5.0. III. To determine PFS1, event free survival (EFS) and overall survival (OS) in each study arm (A and B). IV. To determine the overall response rate (ORR) and complete response rate (CR) after restarting zanubrutinib, following the first progression, in the intermittent treatment arm (Arm B). V. To compare burden of symptomatic adverse events (AEs) as assessed by Patient-Reported Outcome Common Terminology Criteria for Adverse Events (PRO-CTCAE) between patients randomized to Arm A versus Arm B. QUALITY OF LIFE PRIMARY OBJECTIVE: I. To compare health-related quality of life (QOL) at 12 cycles post-randomization as assessed by the Functional Assessment of Cancer Therapy (FACT) Lymphoma Symptom Index-18 (FLYMSI-18) total score between patients randomized to Arm A versus Arm B. QUALITY OF LIFE SECONDARY OBJECTIVES: I. To compare health-related QOL at other time points as assessed by the FLYMSI-18 total score between patients randomized to Arm A versus Arm B. II. To compare burden of symptomatic AEs as assessed by PRO-CTCAE between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment. QUALITY OF LIFE EXPLORATORY OBJECTIVES: I. To compare the geriatric functional and cognitive PRO as assessed by Elderly Functional Index (EFLI) and Neurology (Neuro) QOL in Arm A versus Arm B. II. To compare cognitive function at various time points as assessed by the Neuro-QOL between patients randomized to continuous (Arm A) versus intermittent (Arm B) zanubrutinib treatment. EXPLORATORY OBJECTIVES: I. To evaluate the completion rate of a lymphoma-specific patient assessment of life survey (PALS) with patient directed questions on life, health, and social determinants of health (SDH) and assess the impact of the survey collected data on outcomes for all enrolled patients (study arms A and B). II. To evaluate minimal residual disease (MRD) in those patients who achieve a CR after induction therapy (arms A and B) and how detectable MRD status changes after continued therapy vs. discontinuation of therapy (i.e. arms A vs. B). OUTLINE: INDUCTION THERAPY: Patients receive zanubrutinib orally (PO) and rituximab intravenously (IV) on study. Patients undergo bone marrow biopsy and fluciclovine F18 (FDG) positron emission tomography (PET)/ computed tomography (CT) or CT throughout the trial. Patients may also undergo esophagogastroduodenoscopy (EGD) and/or colonoscopy on study as clinically indicated. Patients may optionally undergo blood sample collection throughout the trial. MAINTENANCE THERAPY: Patients achieving a CR after induction therapy are randomized to 1 of 2 arms. ARM A: Patients receive zanubrutinib PO until first disease progression on study. Patients undergo CT or magnetic resonance imaging (MRI) or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. ARM B: Patients undergo observation until first disease progression and then receive zanubrutinib PO until second disease progression on study. Patients undergo CT or MRI or FDG PET/CT throughout the trial. Patients may optionally undergo blood sample collection throughout the trial. After completion of study treatment, patients are followed within 30 days and every 6 months for 10 years.